Novartis and Sangamo Therapeutics plan to pursue potential treatments for neurodevelopmental diseases.
Novartis now offers associates the choice to decide how, where and when they work to create the greatest impact for their role while taking personal responsibility to inform managers and align with teammates for effective collaboration, based on the nature of their work.
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.
This site is intended for a global audience.